MSIF is proud to announce the recipients of the 2021 McDonald Fellowships and Du Pré Grants, from Argentina, Brazil, Egypt, Iran, and Tunisia
Register below for the global webcast on fatigue research and treatment
Find out about the lives of seven people affected by progressive MS.
Professor Thompson wins the 2021 lifetime achievement award for outstanding research into the understanding and treatment of MS
In time for World MS Day, €1,425,000 has been awarded to help identify new therapeutic targets in progressive MS
Watch the International Progressive MS Alliance webcast
Research and clinical trials are taking place around the world, trying to find and improve treatments for MS
A first-of-its-kind global research network funded by the International Progressive MS Alliance aims to develop new, effective treatments for progressive MS.
The International Progressive MS Alliance works to speed up the development of treatment for progressive MS
Global webcast on 4 March
This paper was first published in Nature January 2021
MSIF is proud to announce the recipients of the 2020 McDonald Fellowships and Du Pré Grants, from Iran, Zambia, Brazil, Turkey, and Argentina
Register for the Progressive MS Alliance's Facebook Live event
Genetic screening of people with primary progressive MS has shown that four rare genetic changes, which are known to cause other neurological diseases, may play a role in primary progressive MS.
The use of neurofilament light chain (NfL) as a biomarker could revolutionise clinical trials in progressive MS.
Join the discussion about research breakthroughs that could accelerate new treatments for people with progressive MS
New research funded by the International Progressive MS Alliance looks at ways that nerve fibres protect themselves from damage.
Watch the International Progressive MS Alliance webcast here
An International Progressive MS Alliance global webcast
Cord lesion load and spinal cord atrophy may contribute to disability in people with progressive MS
An important milestone for people with secondary progressive MS in Europe
Register for the Progressive MS Alliance's Facebook Live event on symptom management and well-being in progressive MS
Progressive MS Awards
Thousands of scientists are undertaking research into all aspects of MS, furthering our understanding of the disease and how to prevent, treat and manage it.
The International Progressive MS Alliance is growing!
The results of the MS-SMART trial, an innovative trial testing multiple drugs at the same time, have ruled out three repurposed drugs for the treatment of progressive MS.
A phase II clinical trial has shown ibudilast, a repurposed asthma medication, can slow down the rate of brain tissue loss in progressive MS by almost half compared to a placebo treatment.
Researchers, clinicians and people living with MS, from around the world converged on the city of Toronto in Canada for the 3rd Congress of the International Progressive MS Alliance.
How the biological processes cause progression in different types of MS.
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Screening of almost 250 medications has identified clomipramine as a possible treatment for progressive MS.
The European Commission has approved the first disease-modifying therapy, ocrelizumab, for early primary progressive MS (PPMS).
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Neurobiology and immunology are key areas of MS research
Researchers and health professionals gather for the latest updates and research findings on treatment, care and management of MS
Video from Caroline Sincock who recently joined the International Progressive MS Alliance
Our highlights from the world’s largest scientific conference on multiple sclerosis
Challenges and next steps considered
Full text of our 2014 webinar with experts on progressive MS
A recent study has failed to show any benefit for Rituximab in people with secondary progressive MS
A new trial has failed to show Fingolimod has any effect of in primary-progressive MS
Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes
Chemical in the brain involved in signaling may play a role in progressive MS
The Charcot Award recognises a lifetime of achievement in MS research
Collaborative Network Planning Awards Granted as part of €22 million global effort to End Progressive MS
On 6 October, 650 people affected by MS gathered in Barcelona for the ‘Living with MS Day’ event
The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS
Recovery from early relapses can potentially delay or prevent onset of progressive MS
Researchers in Canada have investigated the natural history of 500 people with primary progressive MS
There is a need to identify direct biomarkers of inflammation within the central nervous system
Researchers are looking for new biomarkers of disease, which could also recognise progression of MS in a reasonable time
Study suggests that early spinal neurodegeneration may underlie clinical impairment
Three people needed to help shape the work of the Alliance
Study supports a link between the development of grey matter disease and a progressive MS phenotype
Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS
Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared with historical cohorts
The Alliance has been joined by four MS International Federation member organisations
Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset of progressive MS
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
The Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries
There are four main types of MS: clinically isolated syndrome, relapsing MS, secondary progressive MS and primary progressive MS.